A Phase 1b, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date27/11/19 → 31/12/26

Keywords

  • Medical oncology
  • Advanced/Metastatic solid tumors
  • Clinical trial